$2.37 -0.05 (-2.07%)
2/9/2010 4:00 PM

Achillion Pharmaceuticals, Inc. (ACHN)

CAPS Rating: No stars

A biopharmaceutical company focuses on the discovery, development and commercialization of innovative treatments for infectious diseases

Current Price $2.37 Mkt Cap $63.18M
Open $2.47 P/E Ratio 0.21
Prev. Close $2.42 Div. (Yield) N/A (N/A)
Daily Range $2.32 - $2.51 Volume 344,536
52-Wk Range $1.10 - $3.89 Avg. Daily Vol. 0

ACHN News and Commentary

Related News and Articles

Caps

This ticker is not currently Ratable.

Add Stock to Watchlist

All Members

14 Outperform
3 Underperform
 

All-Star Members

5 Outperform
2 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top ACHN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

ACHN VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about ACHN.

Recs

0
Member Avatar NetscribePhrmtcl (96.01) Submitted: 3/20/2007 8:42:53 AM : Underperform Start Price: $7.06 ACHN Score: +44.16

Achillion is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. Within the anti-infective market, the company concentrates on the development of antivirals and antibacterials. It is targeting the antiviral development efforts on treatments for HIV infection and chronic hepatitis C, and is directing its antibacterial development efforts toward treatments for serious hospital-based bacterial infections.

Its two lead drug candidates are Elvucitabine, which is in the Phase II clinical trials in HIV-infected patients, and ACH-806, which the company is evaluating in collaboration with Gilead Sciences in a Phase I clinical trial for the treatment of chronic hepatitis C. The company is also evaluating its third drug candidate, ACH-702, in late-stage, pre-clinical studies for the treatment of serious hospital-based bacterial infections.

Revenues witnessed a sharp 91% decline for the quarter ended September 2006. The decrease in 2006 is the result of a reduction in milestone payments under collaboration with Gilead Sciences. Net loss applicable to common shareholders increased 71%, reflecting a sharp increase in R&D expenses and administrative costs. The company has incurred losses of $100 million from inception to September 2006 and had an accumulated deficit of $113.6 million through September 30, 2006.

Achillion appears to be a weak investment proposition based on the delay in the expected development timeline for the HIV & HCV program. The launch of a replicase inhibitor for HCV is expected to be in 2011, rather than 2010, which would hamper the company’s near term earning prospects.

Recs

0
Member Avatar turingmouse (56.72) Submitted: 2/12/2007 2:05:24 AM : Outperform Start Price: $9.22 ACHN Score: -53.36

took to much of a beating on hep-c trial news. should outperform.

Leaderboard

Find the members with the highest scoring picks in ACHN.

Score Leader

dimitri109

dimitri109 (99.91) Score: +72.29

The Score Leader is the member with the highest score across all their picks in ACHN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score Commentary
ceoofwhoopass 52.86 2/12/2007 Underperform 3W $9.22 -74.30% -20.94% +53.36
MassProduced 97.04 2/16/2007 Underperform NS $8.86 -73.25% -21.75% +51.50
NetscribePhrmtcl 96.01 4/16/2007 Underperform 1Y $7.06 -66.43% -22.27% +44.16 1 Comment
KennerHK < 20 9/13/2007 Outperform 3M $6.82 -65.25% -24.02% -41.23
pinksheetbasher < 20 8/22/2007 Outperform NS $6.92 -65.75% -22.68% -43.08
llamataboot 78.02 3/7/2007 Outperform 1Y $7.32 -67.62% -18.73% -48.89
justiny 98.46 2/22/2007 Outperform NS $8.32 -71.51% -22.08% -49.44
SanDieguito < 20 2/9/2007 Outperform NS $8.61 -72.47% -21.59% -50.88
AlpacaInvestor 96.27 2/9/2007 Outperform 3W $8.61 -72.47% -21.59% -50.88
Lolly131313 96.86 2/9/2007 Outperform 5Y $8.82 -73.13% -21.48% -51.65

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackSwensen 31.46 9/30/2007 Outperform NS $6.46 -22.76% -4.17% -18.58 12/31/2007 @ $4.99 1 Comment
TrackCowenandCo 86.76 12/7/2006 Outperform NS $17.25 -86.26% -19.95% -66.31
TrackJMP 71.98 12/6/2006 Outperform NS $16.76 -90.75% -36.55% -54.21 5/18/2009 @ $1.55

Featured Broker Partners